Clinical trial

Exercise Effects on Cardiometabolic Health and Sestrin-2 in Hypertensive Obese Women

Opening soon · Not applicable · 1 countries · Registry ID NCT07370363

Opening soonNot applicableInterventional

What this study is about

Obesity is a chronic and complex disease characterized by excessive fat accumulation that adversely affects health and quality of life. It is commonly accompanied by low-grade chronic systemic inflammation, which contributes to the development of insulin resistance, type 2 diabetes, dyslipidemia, hypertension, and cardiovascular diseases. Hypertension is highly prevalent among individuals with obesity, and excess body weight is a major contributor to elevated blood pressure and related cardiometabolic risk. Regular aerobic exercise is a cornerstone of non-pharmacological management for both obesity and hypertension and has been shown to reduce chronic inflammation by downregulating pro-inflammatory pathways and upregulating anti-inflammatory mechanisms. Sestrin-2, a stress-responsive protein encoded by the SESN2 gene, has been proposed as an important regulator of metabolic homeostasis and inflammation through activation of the AMPK pathway and inhibition of NF-κB signaling. However, evidence regarding the effects of different exercise modalities on circulating Sestrin-2 levels in hypertensive obese individuals remains limited. This prospective, randomized controlled trial aims to compare the effects of two different aerobic exercise protocols on serum Sestrin-2 levels, inflammatory status, and cardiometabolic parameters in hypertensive obese women. Cardiopulmonary exercise testing will be used to comprehensively assess cardiorespiratory fitness and physiological responses to exercise. The results of this study are expected to contribute to a better understanding of exercise-induced anti-inflammatory mechanisms and to support the development of safe, effective, and applicable exercise prescriptions for hypertensive obese women.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age30 Years to 65 Years

SexFemale

Healthy volunteersNot accepted

ConditionObesity, Hypertension

Full registry criteria

Inclusion Criteria: * Female participants aged between 30 and 65 years * Body mass index between 30.0 and \<40.0 kg/m² (Class I and Class II obesity) * Diagnosis of hypertension according to the 2018 European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines * Sedentary lifestyle, defined as total weekly exercise duration of less than 60 minutes * Medically eligible for exercise participation, with approval from a Physical Medicine and Rehabilitation specialist and an Internal Medicine specialist * Willingness to participate in the study and provision of written informed consent Exclusion Criteria: * Neuromuscular disorders, uncontrolled psychiatric diseases, or cognitive impairment limiting exercise participation * Congestive heart failure, unstable angina, or acute cardiac conditions including acute myocardial infarction, acute endocarditis, myocarditis, or pericarditis * Presence of uncontrolled systemic diseases, including: * Uncontrolled hypertension * Uncontrolled diabetes mellitus * Chronic liver failure * Chronic kidney disease or patients receiving dialysis * Chronic obstructive pulmonary disease or asthma * History or presence of malignancy * Acute infection at the time of enrollment * Acute peripheral vascular disease * Symptomatic severe aortic stenosis * Acute pulmonary embolism or pulmonary infarction * Use of systemic corticosteroids or immunosuppressive medications * Inability to comply with the study protocol or lack of cooperation * Refusal to participate in the study

Treatments and study arms

Moderate-Intensity Continuous Exercise

Behavioral

Supervised moderate-intensity continuous aerobic exercise performed at a prescribed intensity and frequency for the duration of the intervention period.

Brisk Interval Exercise

Behavioral

Supervised interval aerobic exercise consisting of alternating bouts of higher and moderate intensity performed throughout the intervention period.

Primary outcomes

Serum Sestrin-2 LevelBaseline and end of 8-week intervention

Serum Sestrin-2 levels will be measured using enzyme-linked immunosorbent assay (ELISA). Blood samples will be collected 48 hours before the start of the 8-week exercise program and 48 hours after completion of the intervention in order to avoid the acute effects of exercise. The primary outcome is the change in Sestrin-2 levels from baseline to post-intervention.

Maximal Oxygen Consumption (VO2max)Baseline and end of 8-week intervention

VO2max will be assessed using cardiopulmonary exercise testing (CPET) according to standardized protocols. Measurements will be performed before the start of the exercise program and after completion of the 8-week intervention. The change in VO2max from baseline to post-intervention will be analyzed.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Kayseri City Hospital🌐 Kayseri, Kayseri, Turkey (Türkiye)

Open map

Rukiye Akay, MDContact

Email · Call 05392333789